On Wednesday, Alaska Air Group, Inc. (NYSE:ALK)’s shares gained 3.27%, and closed at $64.81, after Alaska Air Group, and Horizon Air Industries, Inc., will declare its first quarter 2015 financial results on Thursday, April 23, 2015. A conference call is planned at 8:30 a.m. Pacific time/11:30 a.m. Eastern time. Interested parties may listen to the call via webcast at www.alaskaair.com/investors.
Alaska Airlines, a partner of Alaska Air Group (ALK), together with its partner regional airlines, serves more than 100 cities through an expansive network in the United States, Canada and Mexico.
Alaska Air Group, Inc., through its auxiliaries, provides passengers and cargo air transportation services primarily in the United States. The corporation operates through Alaska Mainline and Alaska Regional segments. It serves about 100 cities in Alaska, the Lower 48, Hawaii, Canada, and Mexico.
Achillion Pharmaceuticals, Inc. (NASDAQ:ACHN)’s shares jumped 3.27%, and settled at $10.28, during the last trading session on Wednesday, after a biopharmaceutical corporation, declared that it will present three posters, counting two late breaker abstracts, at the 50th Annual Meeting of the European Association for the Study of the Liver (EASL) during The International Liver Congress 2015. Poster presentations will comprise Phase 1 results on ACH-3422, a NS5B nucleotide polymerase inhibitor, and detailed results from the Phase 2 proxy study evaluating ACH-3102, a second-generation NS5A inhibitor, and sofosbuvir following 6- and 8-week treatment durations for treatment-naive genotype 1 HCV. The congress is being held April 22 — 26 in Vienna, Austria. The abstracts can be accessed on the EASL website at https://ilc-congress.eu/ and posters will be accessible following their presentation under the resources section of the Achillion website at http://www.achillion.com.
Achillion Pharmaceuticals, Inc., a biopharmaceutical corporation, discovers, develops, and commercializes anti-infective drug therapies in the United States and internationally. It focuses on developing combination therapies for the treatment of chronic hepatitis C (HCV) infection and drug-resistant bacterial infections.
At the end of Wednesday’s trade, Shire plc (NASDAQ:SHPG)’s shares climbed 3.20%, and closed at $247.08, after a biopharmaceutical corporation, declared that it has reached a contract with the U.S. Food and Drug Administration (FDA) on a clear regulatory path for SHP465 (triple-bead mixed amphetamine salts - MAS), an investigational oral stimulant medication being evaluated as a potential treatment for Attention-Deficit/Hyperactivity Disorder (ADHD) in adults.
Shire has agreed with the FDA to conduct a short-term efficacy and safety study in pediatric patients with ADHD (ages 6-17). While Shire intends to pursue an adult indication, the FDA is requesting this additional pediatric data to better understand the potential effects of SHP465 on children with ADHD in the event of use in this population. The Corporation anticipates the clinical trials first patient, first visit to take place in August 2015, with study completion targeted by the last quarter of 2016. Shire then anticipates to submit to the FDA by second quarter 2017 a Class 2 resubmission for approval of SHP465 as a treatment for ADHD in adults, which typically entails a 6-month review. Pending FDA approval, Shire anticipates launching the medicine in the second half of 2017. This update follows Shire’s declaration on October 9, 2014, that it was engaging the FDA to determine the parameters of clinical data requirements in order to submit the Class 2 resubmission.
Shire plc, a biopharmaceutical corporation, together with its auxiliaries, researches, develops, licenses, manufactures, markets, distributes, and sells pharmaceutical products. It offers various products for the treatment of attention deficit hyperactivity disorder (ADHD), counting VYVANSE/ VENVANSE/ ELVANSE/ TYVENSE/ ELVANS E VUXEN/ADUVANZ; INTUNIV, an alpha-2A receptor agonist; EQUASYM, a methylphenidate hydrochloride; and ADDERALL XR, an extended release treatment for ADHD. The corporation also provides BUCCOLAM for epilepsy treatment; PENTASA and LIALDA/MEZAVANT for ulcerative colitis treatment; and RESOLOR, a 5-HT4 receptor agonist that is used for the treatment of chronic constipation in women.
Mallinckrodt public limited Company (NYSE:MNK), ended its Wednesday’s trading session with 3.13% gain, and closed at $128.03, as Mallinckrodt public limited, will report second quarter fiscal 2015 results on Tuesday, May 5, 2015. A conference call for investors will start at 8:30 a.m. U.S. Eastern Time.
A replay of the call will be accessible starting at 11:30 a.m. U.S. Eastern Time on Tuesday, May 5, 2015, and ending at 11:59 p.m. U.S. Eastern Time on Tuesday, May 12, 2015. Dial-in numbers for U.S.-based participants are (855) 859-2056 or (800) 585-8367. Participants outside the United States should use the replay dial-in number (404) 537-3406. All callers will be required to provide the Conference ID of 22730989.
Mallinckrodt public limited corporation develops, manufactures, markets, and distributes specialty pharmaceutical products and medical imaging agents worldwide. The corporation operates through two segments, Specialty Pharmaceuticals and Global Medical Imaging.
DISCLAIMER:
This article is published by www.wsnewspublishers.com. The Content included in this article is just for informational purposes only. All information used in this article is believed to be from reliable sources, but we make no representations or warranties of any kind, express or implied, about the completeness, accuracy, or reliability with respect to this article.
All visitors are advised to conduct their own independent research into individual stocks before making a purchase decision.
Information contained in this article contains forward-looking information within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934, counting statements regarding the predictable continual growth of the market for the corporation’s products, the corporation’s ability to fund its capital requirement in the near term and in the long term; pricing pressures; etc.
Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, objectives, aims, assumptions, or future events or performance may be forward looking statements. Forward-looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements may be identified through the use of such words as expects, will, anticipates, estimates, believes, or by statements indicating certain actions may, could, should might occur.
